Hosted on MSN2mon
89bio stock rallies 40% amid data for rival MASH drug
Akero (NASDAQ:AKRO) shares soared Monday on encouraging data from a Phase 2b study of efruxifermin in the treatment of patients with compensated cirrhosis (F4) due to MASH, also known as metabolic ...
The American Journal of Managed Care11d
MASH Clinical Trials Historically Underrepresent Certain Groups
Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...